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Precis: We provide a correlation between USP8 mutations and expression of key proteins in 31 
corticotroph tumors suggesting these proteins to be USP8 substrates and potential treatment 32 
targets against CD.  33 
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Abstract 34 
Context Cushing’s disease (CD) is a rare disorder with severe sequels and incompletely 35 
understood pathogenesis. The underlying corticotroph adenomas harbor frequently somatic 36 
mutations in the ubiquitin-specific peptidase 8 (USP8) gene. These mutations render USP8 37 
hyperactive and prevent client proteins from degradation. 38 
Objective To investigate the impact of USP8 mutations on proteins deregulated in CD. 39 
Design 108 pituitary adenomas (75 corticotroph (58 USP8 wildtype (WT) and 17 USP8 40 
mutated), 14 somatotroph and 19 non-functioning) were investigated by 41 
immunohistochemistry. All evaluated proteins (USP8, AVP receptor 1b & 2, CRH receptor, 42 
CREB, p27/kip1, cyclin E, HSP90, TR4, EGFR, HDAC2, GR, Cables1) were known to be 43 
deregulated in CD. Furthermore, AtT20 cells were transfected with USP8 to investigate the 44 
expression of possible downstream proteins by immunoblot.  45 
Results Whereas most of the investigated proteins were not differentially expressed, the cell 46 
cycle inhibitor p27 was significantly reduced in USP8 mutated corticotroph adenoma (H-score 47 
2.0±1.0 vs 1.1±1.1 in wt adenomas; p=0.004). In contrast, the chaperone HSP90 was higher 48 
expressed (0.5±0.4 vs. 0.2±0.4; p=0.29) and the phosphorylation of the transcription factor 49 
CREB was increased in USP8 mutated adenomas (1.30.5±0.40.9 vs. 0.70.5±0.40.7; P=0.014). 50 
Accordingly, AtT20 cells transfected with USP8 P720R mutant had higher pCREB levels than 51 
WT transfected cells (1.3 ±0.14 vs 1 ±0.23; p=0.13).  52 
Conclusions We could demonstrate that USP8 mutations are associated with deregulation of 53 
p27/kip1, HSP90, and phosphorylated CREB. These findings suggest that these proteins are 54 
direct or indirect clients of USP8 and could therefore be potential targets for therapeutic 55 
approaches in patients with CD.   56 
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Introduction  57 
Cushing’s disease (CD) is a rare (incidence: 2-4 per million [1]) but life-threatening endocrine 58 
disorder caused by adrenocorticotropic hormone (ACTH)-secreting (corticotroph) pituitary 59 
adenomas. It is associated with increased morbidity and mortality resulting from chronic 60 
exposure to glucocorticoids, secreted by the adrenal cortex in response to ACTH stimulation. 61 
Patients with CD often suffer from hypertension, diabetes mellitus, proximal myopathy, and 62 
skin atrophy [2]. Accordingly, the majority of deaths associated with CD is caused by 63 
cardiovascular, metabolic, and infectious complications. Treatment options include surgical 64 
resection of the tumor, irradiation of the sellar region, and medical therapy [3]. However, the 65 
available drugs mainly combat the symptoms but not the cause, acting as blockers of the 66 
glucocorticoid receptor (GR) (e.g. mifepristone) and inhibitors of either ACTH release (e.g. 67 
dopamine agonists, somatostatin analogs) or cortisol secretion (e.g. metyrapone, 68 
ketoconazole) [4, 5]. These drugs may have several adverse effects and often also limited 69 
efficacy, thus improved pharmacological options are needed (but require an improved 70 
understanding of the molecular events causing CD). The definitive treatment of CD is bilateral 71 
adrenalectomy which is taken under consideration if other treatments or medication have failed 72 
[6]. However, one complication of bilateral adrenalectomy is Nelson’s syndrome, an aggressive 73 
pituitary tumor that occurs in a small subset of patients [7]. In the last years, important insights 74 
in the development of CD have been gained, including the major finding of somatic mutations 75 
in the deubiquitinase ubiquitin-specific peptidase 8 (USP8) gene in almost half of ACTH-76 
secreting adenomas [8-10]. These mutations were shown to render USP8 hyperactive, 77 
resulting in increased recycling of its substrates like the receptor tyrosine kinase (RTK) 78 
epidermal growth factor receptor (EGFR), leading ultimately to increased proliferation and 79 
increased ACTH secretion [8] bypassing the negative feed-back control exercised through the 80 
GR. In addition, other proteins are known to be deregulated in corticotroph tumors like the 81 
family of arginine vasopressin receptors (AVPR1b and 2) and the corticotropin releasing 82 
hormone receptor (CRHR), both not only involved in ACTH release of the anterior pituitary but 83 
also overexpressed in corticotroph tumors [11-15]. Quite recently, also the chaperone heat 84 
shock protein 90 (HSP90) and the orphan nuclear receptor 4 (TR4) were shown to be 85 
overexpressed in corticotropinomas compared to normal pituitaries [16, 17]. While HSP90 is 86 
involved in proper GR folding [16], TR4 induces POMC (pro-opiomelanocortin) promoter 87 
transcription [17]. In addition, the histone deacetylase HDAC2 (which deacetylates histone H4 88 
at the POMC promoter, thereby leading to the repression of POMC transcription) was shown 89 
to have a reduced expression in a subset of corticotroph tumors [18]. Apart from proteins 90 
obviously involved in ACTH hypersecretion, expression or activity of proteins contributing to 91 
cell proliferation and tumorigenesis were reported to be modified in corticotroph tumors. These 92 
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include the upregulation of cyclin E [19, 20] and EGFR [21, 22] on the one hand, and the 93 
downregulation of cyclin-dependent kinase (CDK) inhibitor p27/Kip1 [23-25] on the other. 94 
Furthermore, CABLES1, a negative regulator of cell cycle progression is activated in response 95 
to glucocorticoids and its expression was shown to be lost in approximately half of corticotroph 96 
tumors [26]. Additionally, mutations in the CABLES1 gene were described as a rare cause for 97 
CD [27]. Although a direct link between EGFR signaling and USP8 mutations has been 98 
suggested by in vitro studies [8, 28], Hayashi and colleagues did not observe activated EGFR 99 
signaling in several USP8 mutated tumors with increased levels of POMC mRNA [29] . Thus, 100 
it is likely that activated EGFR signaling is not exclusively responsible for increased ACTH 101 
secretion in USP8-mutated corticotroph tumors. Other candidates might be the already 102 
mentioned deregulated proteins, but also proteins in the cAMP/protein kinase A (PKA) 103 
signaling pathway. The latter have been shown to promote ACTH secretion [30], and there is 104 
a possibility that increased PKA signaling could be due to deubiquitination through USP8. The 105 
aim of this study was to find putative USP8 client proteins that could contribute to the ACTH 106 
over-secretion and/or tumorigenesis in CD. For this, we evaluated whether already reported 107 
deregulated proteins associated with CD have a significantly altered expression when 108 
comparing corticotroph USP8 WT and mutated tumors. 109 
 110 
 111 
Methods 112 
Tissue collection 113 
In total, we investigated 108 formalin-fixed paraffin-embedded (FFPE) pituitary tumors 114 
(corticotroph (n=75), somatotroph (GH-secreting, n=14) and non-functioning (n=19) from 115 
individual patients. At the University Hospital Hamburg, 51 corticotroph pituitary adenomas 116 
were assembled into one tissue microarray (TMA). In order to choose representative areas 117 
with well-preserved morphology of each adenoma, haematoxylin and eosin stained tissues 118 
were re-evaluated by one experienced pathologist (WS), marking the corresponding area for 119 
tissue punching. Two cores with a diameter of 0.6 mm were punched from each tissue block 120 
and arrayed into a new block. Full FFPE slides were used in 24 corticotroph, 12 somatotroph 121 
and 19 non-functioning adenomas; these samples had been collected at the University of 122 
Wuerzburg. In addition, normal pituitaries (nP) (n=5) were available from autopsies performed 123 
at the University Hospital Wuerzburg.  124 
Patients and clinical annotations 125 
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For patients with corticotroph adenomas key clinical characteristics are listed in table 1. 126 
Diagnosis of CD was performed according to established clinical, biochemical and 127 
morphological criteria [31]; the same was true for other pituitary tumor entities. All patients 128 
gave written informed consent and the study was approved by the Ethics Committees of the 129 
University Hospital Wuerzburg and the Chamber of Physicians in Hamburg.  130 
 131 
DNA extraction from FFPE tissue 132 
Full FFPE tissue slides of each 24µm were used to extract DNA, using the QIAamp® DNA 133 
FFPE Tissue Kit (Qiagen) according to the manufacturer’s instructions. Elution was performed 134 
in 30µl H2O. DNA quality and concentration were determined with the Nanodrop 135 
spectrophotometer (Thermo).  136 
 137 
Sanger Sequencing  138 
Sanger sequencing was used to determine the USP8 mutation status. Two primers were used, 139 
spanning a length of 266 bp around the 14-3-3 binding domain of USP8: USP8fw: 140 
ATATGTACCCACCGGAAATG and USP8rev: CAGAGTAGAAACTTTGAAATACAGCA. For 141 
amplification of the PCR product in the following reaction, 30-60 ng of DNA was used: 96 °C 142 
for 2 min, 10 cycles with 96 °C for 30 sec, 58 °C for 30 sec, and 72 °C for 30 sec. 20 cycles 143 
were followed with a reduced annealing temperature of 56 °C. The same primers were used 144 
in the sequencing reaction. Results were analyzed with the Genome Genetic Analysis System 145 
(ABSciex). 146 
 147 
Chromogenic Immunohistochemistry  148 
Slides were deparaffinised in xylol twice before being rehydrated, and antigen retrieval was 149 
performed in 10 mM citric acid monohydrate buffer (pH 6.5) within a pressure cooker for 13 min. 150 
Endogenous peroxidase was blocked with 3% H2O2 in methanol for 10 min, and unspecific 151 
binding sites were blocked in 20 % human AB serum at room temperature for 1 hour. Primary 152 
antibodies were diluted in PBS and incubated at room temperature for 1 hour. The following 153 
antibodies were used: USP8 (Sigma #HPA004869, 1:500), HSP90 (abcam #EPR3953, 1:500), 154 
TR4 (Sigma #HPA006313, 1:200), Cyclin E (Santa Cruz #sc-481 1:400), p27/kip1 (BD 155 
#610242 1:1000), CREB (cAMP response element-binding protein)  (Cell Signaling #9197 156 
1:500), pCREB (Cell Signaling #9198 1:500), CRHR (LSBio #LS-A6687/41992 1:250), 157 
AVPR1B (LSBio #LS-A3737/41899 1:250), EGFR (Santa Cruz SC-03 1:500), AVPR2 (LSBio 158 
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#LS-B8250/135767 1:250), GR (Cell Signaling #12041 1:400), HDAC2 (abcam #ab32117 159 
1:1600), CABLES1 (abcam #ab75535 1:2000) and N-Universal Negative controls anti-rabbit 160 
or anti-mouse (Dako). Signal amplification was performed with Advance HRP Link Kit (Dako) 161 
for 40 min and development with DAB+ Liquid Kit (Dako) for 10 min. Nuclei were 162 
counterstained with Mayer’s hematoxilin for 2 min and blueing was performed for 5 min in 163 
running tap water. Stained slides were dehydrated in 100 % EtOH and dried at 56 °C for 30 164 
min before mounting with Entellan. 165 
Semiquantitve analysis of immunoreactivity 166 
Staining intensities were always determined by two independent investigators (I. W. & L. K. or 167 
S. S.) and graded 0 (negative), 1 (low), 2 (medium), and 3 (high). The proportion of positive 168 
tumor cells was calculated for each specimen and scored 0 if 0 % were positive, 0.1 if 0.1-9 % 169 
were positive, 0.5 if 10-49% were positive and 1 if ≥50 % were positive. Cytoplasmic and / or 170 
membranous staining and nuclear staining were analyzed independently. A semi-quantitative 171 
H-score was then calculated by multiplying the staining intensity grading score with the 172 
proportion score as described previously [32]. In case of discrepant results, both investigators 173 
jointly assessed the respective stainings, and the final H score was formed by consensus. 174 
Cell culture and transfections 175 
In order to investigate the expression of possible downstream proteins, the murine corticotroph 176 
adenoma cell line At-T20 was transfected not only with different USP8 constructs (WT, P720R) 177 
but also with empty vector (mock). Cells were seeded into 6 well plates (5x10^5/ well) and 178 
transfected with 1µg DNA 24 h later, using Effectene (Qiagen) according to the manufacturer’s 179 
instructions. USP8 WT and P720R plasmids were donated by Professor Marily 180 
Theodoropoulou (Ludwig Maximilian Universität, Munich, Germany) [8] . 48 h post transfection, 181 
cells were lysed in RIPA buffer, containing protease and phosphatase inhibitors (Sigma).  182 
Immunoblots 183 
10µg of protein lysates were loaded onto polyacrylamide gradient gels (4-12%, Bio-Rad) and 184 
transferred to a PVDF membrane. Antibodies were incubated overnight in 5 % blocking 185 
solution and developed on an x-ray film. The following primary antibodies were used: USP8 186 
(Sigma #HPA004869, 1:1000), p-CREB (Cell Signaling #9198 1:500), PKA Cα (BD 5B 1:1000), 187 
α-tubulin (housekeeping gene) (Sigma: DM1A 1:20000) and secondary antibodies: goat-α-188 
rabbit-HRP (Jackson ImmunoResearch: 1:10000) and goat-α-mouse-HRP (Jackson 189 
ImmunoResearch: 1:10000). Protein-antibody complexes were visualised using the 190 
Amersham ECL Prime reagent (GE Healthcare). 191 
 192 
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Statistical analysis 193 
The Mann-Whitney-U test was performed to determine statistically significant differences 194 
between two non-parametric datasets. One-way ANOVA test with Tuckey post-hoc test was 195 
done to determine significant differences between different groups of samples. For statistical 196 
analyses, GraphPad Prism (version 6.0) was used. P values < 0.05 were considered as 197 
statistically significant.  198 
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Results 199 
Protein expression pattern in USP8 WT vs USP8 mutated corticotroph adenomas 200 
As already described in the original report [8], cytoplasmatic expression of USP8 was 201 
unchanged between USP8 WT and mutated tumors (H-score 1.1±0.6 (WT) vs 1.2±0.5 (mut); 202 
p=0.49), but nuclear USP8 was predominant in USP8 mutated tumors (0.7±0.6 (WT) vs 203 
1.6±0.8 (mut); p=0.0001), (figure 1 (a) & (b)). EGFR levels were similar in the nucleus (0.6±0.6 204 
(WT) vs 0.6±0.8 (mut) p=0.76), while significantly lower in the membrane in USP8 mutated 205 
compared to USP8 WT adenomas (1.3±0.7 (WT) vs 0.9±0.3 (mut) p=0.04), (figure 1 (a) & (c)). 206 
The cell cycle inhibitor p27/kip1 is significantly decreased in USP8-mutated 207 
corticotroph tumors 208 
The cyclin-dependent kinase inhibitor p27/kip1 has been shown to be downregulated in 209 
corticotroph tumors [21, 23-25]. By analysing USP8 WT and mutated adenomas 210 
independently, a reduction in p27/kip1 expression was observed in USP8-mutated adenomas 211 
in both the cytoplasm (1±0.7 vs 0.4±0.6; p=0.003) and the nuclei (2±1 vs 1.1±1.1; p=0.004) 212 
(figure 1 (a) & (d)). Compared to the other tumor entities, p27/kip1 expression was also only 213 
reduced in USP8-mutated but not in USP8 WT tumors (figure 1(d)). Another cell cycle 214 
regulator, Cyclin E, has been described as overexpressed in corticotroph tumors [19, 20]. In 215 
our cohort, Cyclin E was indeed stronger expressed in all pituitary tumors, independent of their 216 
specific hormone secretion compared to the normal pituitary. However, its expression in 217 
corticotroph tumors was independent of USP8 mutation status (WT vs mut, cytoplasm: 1.7±0.7 218 
vs 1.5±0.7; p= 0.199, nuclei: 0.8±0.6 vs 0.7±0.5; p=0.533) (figure 1 (a) & (e)). 219 
CREB (cAMP response element-binding protein) is significantly stronger 220 
phosphorylated in USP8-mutated than in USP8 WT corticotroph adenomas 221 
It has been demonstrated that the cAMP/PKA signaling pathway (including CREB) is involved 222 
in POMC promoter activation [33] and ACTH release from cells of the anterior pituitary gland 223 
[30]. We therefore investigated the expression of CREB and its activated form, phospho-224 
CREB, both in USP8 WT and USP8 mutated corticotroph tumors. Since CREB is a 225 
transcription factor, both forms were predominantly localised to the nucleus. However, CREB 226 
was also weakly expressed in the cytoplasm (figure 1(a) & (f)) whereas phospho-CREB was 227 
exclusively nuclear (figure 1(a) & (g)). While CREB protein levels did not differ between USP8 228 
WT and USP8 mutated tumors (neither in the cytoplasm (0.6±0.5 vs 0.4±0.6; p=0.23) nor in 229 
the nucleus (2±1 vs 2.1±0.9; p=0.65) (figure 1 (a) & (f))), nuclear levels of phospho-CREB were 230 
significantly higher in USP8-mutated adenomas (0.7±0.7 vs 1.3±0.9; p=0.014). Compared to 231 
normal pituitaries, nuclear CREB protein expression was higher in all pituitary tumor entities 232 
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(figure 1(f)) (p<0.05), with similar results for phospho-CREB, even if to a lesser extent (figure 233 
1(g)). Since CREB is phosphorylated by the catalytic subunits of PKA (PKA Cα), we analyzed 234 
the expression of the PKA catalytic subunit α in a subset of these tumors (supplementary figure 235 
2 [34]) and found a stronger expression of this subunit in USP8 mutated tumors compared to 236 
USP8 WT tumors. Nevertheless, this difference was not statistically significant. 237 
Expression of the orphan nuclear receptor 4 (TR4) expression is not changed between 238 
corticotroph USP8 WT and mutated tumors 239 
More recently, orphan transcription factor TR4 (also known as NR2C2) was demonstrated to 240 
be significantly overexpressed in corticotroph tumors compared to normal pituitary glands [16, 241 
17]. In our cohort, the expression of TR4 was unchanged between USP8 WT and mutated 242 
tumors, both in the cytoplasm (0.8±0.6 vs 0.6±0.6; p=0.215) and in the nuclei (2.0±0.8 vs 2.1±1; 243 
p=0.471) (figure 1 (a)  & (h)) or when compared to other pituitary tumors (figure 1(h)). 244 
Further differential protein expression analyses in corticotroph USP8 WT and mutated 245 
tumors 246 
We also examined the expression of several markers closely related to corticotroph 247 
deregulation in corticotroph adenomas and normal pituitaries. AVPR1b protein levels were 248 
extremely low in corticotroph adenomas, but were comparable between USP8 WT and USP8 249 
mutated cells (membranous: 0.07±0.2 (WT) vs 0.08±0.1 (mut); p=0.166 and completely absent 250 
expression within the nucleus) (figure 2(a) & (b)). In contrast, the 5 normal pituitaries had 251 
significantly higher protein levels of AVPR1b in comparison to corticotroph adenomas 252 
independent of their mutation status (cytoplasmatic/membranous: 1.8±0.4 vs. 0.07±0.2; 253 
p<0.0001) (see supplementary figure 1 [34]). Expression of AVPR2 was in general relatively 254 
high: its expression varied from H-score 0 to 3 in both USP8 WT and mutated corticotroph 255 
tumors (figure 2(a) & (c)). There was no significant difference in AVPR2 expression between 256 
USP8 WT and mutated corticotroph adenomas in either cytoplasm (1.5±1 (WT) vs 1.5±1.2 257 
(mut), p=0.94) or nucleus (0.1±0.3 (WT) vs 0.1±0.3 (mut), p=0.66).   258 
H-scores for CRHR expression were also largely unaffected by the USP8 mutation status, with 259 
similar expression levels between USP8 WT and USP8 mutated corticotroph adenomas 260 
(membranous: 1.4±0.6 (WT) vs 1.3±0.7 (mut), p=0.95) (figure 2(a) & (d)).  261 
When we investigated the expression of the glucocorticoid receptor itself in corticotroph 262 
adenomas and normal pituitaries, we did not observe significant differences between USP8 263 
WT and mutated adenomas (figure 2(a) & (e)). Cytoplasmatic staining was very low in 264 
corticotroph tumors (0.3±0.5 (WT) vs 0.1±0.3 (mut), p=0.13), while nuclei staining was high in 265 
most samples (2±0.9 (WT) vs 2±1 (mut), p=0.9).  266 
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The expression of HDAC2 in corticotroph adenomas was previously shown to be reduced, 267 
resulting in glucocorticoid resistance and promoting CD [18]. In our cohort, HDAC2 expression 268 
was exclusively nuclear (figure 2(a) & (f)), with only slightly higher expression in USP8 mutated 269 
adenomas compared to USP8 WT adenomas (1.6±0.9 (WT) vs 2.1±0.8 (mut), p=0.09).  270 
Expression of heat shock protein 90 (HSP90) is increased in USP8-mutated tumors  271 
More recently, HSP90, a chaperone involved in proper glucocorticoid receptor (GR) folding 272 
was found to be overexpressed in corticotroph adenomas [16]. 273 
To investigate whether this could be due to mutation induced USP8 hyperactivity, we analyzed 274 
HSP90 expression. HSP90 was not differentially expressed between USP8 WT and mutated 275 
adenomas in the cytoplasm (1.9±0.9 (WT) vs 1.7±1.0 (mut); p=0.448), however, its expression 276 
was significantly increased in the nucleus of mutated adenomas (0.2±0.4 (WT) vs 0.5±0.4 277 
(mut); p=0.029) (figure 2(a) & (g)). As observed by Riebold et al. [16], HSP90 expression was 278 
higher in corticotroph tumors than in normal pituitaries.  279 
Expression of CABLES1 is reduced in USP8-mutated tumors 280 
It has been reported that expression of the negative cell cycle regulator CABLES1 is absent in 281 
about half of corticotroph tumours and that CABLES1 expression correlates with p27/kip1 282 
expression [26]. When we analyzed the expression of CABLES1 in corticotroph tumors with 283 
known USP8 mutation status, we observed a reduction in CABLES1 expression in mutated 284 
adenomas compared to USP8 WT adenomas, both in the cytoplasm and in the nucleus. 285 
However, this reduction was only significant in the cytoplasm (1.1±0.7 (WT) vs 0.6±0.6 (mut), 286 
p=0.012) but not in the nucleus (1.3±1.1 (WT) vs 0.8±0.9 (mut), p=0.23)  (figure 2(a) & (h)).   287 
USP8 mutation increases the levels of phosphorylated CREB in the corticotroph 288 
adenoma cell-line At-T20  289 
In USP8-mutated adenomas, we did not only observe increased levels of phosphorylated 290 
CREB (figure 1(g)) but also a tendency for increased nuclear expression of the PKA catalytic 291 
subunit α in USP8 mutated adenomas (supplementary figure 2 [34]). In order to investigate a 292 
direct link with USP8 mutations, we transiently transfected the murine corticotroph adenoma 293 
cell line At-T20 with USP8 WT, USP8 P720R mutant and empty vector (mock). Cells 294 
transfected with both USP8 plasmids showed an increased expression of USP8 (figure 3(a) & 295 
(b)). Furthermore, cells transfected with the mutated form of USP8 showed increased levels of 296 
phospho-CREB (1.3 ±0.14 vs 1 ±0.23 vs 1,27 ±0.12) and the catalytic subunit α of PKA (1.3 297 
±0.12 vs 1 ±0.38 vs 1.2 ±0.34) compared to cells transfected with USP8 WT or empty vector 298 
(figure 3(a), (c) & (d)).  299 
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Discussion 300 
In recent years, two types of molecular alterations have been reported in the context of CD: 301 
altered expression of different proteins [2, 35] on one hand, and hotspot mutations in the 302 
deubiquitinase gene USP8 on the other (with the latter occurring in around half of the cases) 303 
[8, 10, 28]. The underlying molecular causes for the alterations in protein expression, however, 304 
have often remained elusive. 305 
As starting point of our study, we hypothesized that activating mutations in USP8 might be 306 
responsible for some of these changes. To test this hypothesis, the most relevant of the 307 
previously reported deregulated proteins were investigated immunohistochemically. By looking 308 
at proteins that are differentially expressed between USP8 WT and USP8 mutated adenomas, 309 
which is possibly related to an increased recycling induced by USP8 activating mutations, we 310 
aimed to identify potential USP8 client proteins.  311 
The cyclin dependent kinase inhibitor p27/kip1, which is involved in cell cycle arrest [36], has 312 
often been demonstrated to be down regulated in corticotroph adenomas [23-25]. In our series, 313 
we observed reduced protein expression of p27/kip1 predominantly in USP8 mutated 314 
adenomas, which was significantly reduced when compared to USP8 WT tumors. A 315 
downregulation of p27/kip1 is likely to result in increased cell cycle progression and probably 316 
contributes to cell proliferation. Furthermore, reduced levels of p27/kip1 in corticotroph tumors 317 
have been linked to phosphorylated EGFR at the amino acid residue Tyr992 [21] which is able 318 
to bind phospholipase C – γ (PLC) [37]. The latter, though, has been shown to facilitate the 319 
export of p27/kip1 from the nucleus into the cytoplasm where it is then degraded [38]. In 320 
addition, reduced expression of p27/kip1 was shown to correlate with reduced expression of 321 
CABLES1, a negative regulator of cell cycle progression that is likely a direct glucocorticoid 322 
target [26]. In our cohort, we could confirm this correlation especially with mutated corticotroph 323 
adenomas, showing significantly lower CABLES1 expression contributing to glucocorticoid 324 
resistance (figure 2). Although the phosphorylation status of EGFR in USP8 mutated cells has 325 
not been assessed so far, its expression in USP8 mutated tumors was shown to be increased 326 
at least by some groups [8, 28, 29]. In our cohort, EGFR expression was even reduced in 327 
USP8 mutated tumours compared to WT, making the theory that USP8 hyperactivity and 328 
EGFR recycling directly correlate even more questionable. USP8 mutations seem to be 329 
accompanied by reduced levels of p27/kip1, however, the reason for this change remains 330 
elusive, as there is no indication that p27/kip is regulated through ubiquitination. One might 331 
speculate that another protein is deubiquitinated by USP8, thereby leading to an increased 332 
abundance and reduced p27/kip1 levels. To test if USP8 is in close proximity to p27/kip1, we 333 
performed a proximity ligation assay in a small subset of these tumors. Only in USP8 mutated 334 
adenomas USP8 and p27/kip1 are located in close proximity, possibly in the same complex 335 
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but not in USP8 WT adenomas (supplementary figure 3 [34]). A correlation between reduced 336 
levels of p27/kip1 and USP8 mutations is therefore likely. 337 
It has been repeatedly demonstrated that mutated USP8 is predominantly located within the 338 
nucleus. Consequently, the transcription factor CREB appeared to be a good candidate for 339 
direct regulation by USP8. CREB is not only localized in the nucleus, but also phosphorylated 340 
by PKA; besides, it is involved in POMC promoter activation [33]. Thus, we investigated CREB 341 
in both its unphosphorylated (i.e. inactive) and its phosphorylated (i.e. active) form (figure 1(a), 342 
(f) & (g)). With respect to the nucleus, a significant increase of phosphorylated CREB was 343 
observed in USP8-mutated tumors compared to USP8 WT tumors (figure 1). It has been 344 
outlined that only phosphorylated CREB at serine 133 is able to bind cAMP response elements 345 
(CREs) for induction of POMC promoter activation [39]. Since the expression of 346 
unphosphorylated CREB was not altered between USP8 WT and mutated adenomas, it can 347 
be hypothesized that PKA, which phosphorylates CREB [40], is deregulated. By investigating 348 
the expression of the PKA catalytic subunit α (PRKACA) in a subset of pituitary adenomas, we 349 
found a trend towards increased levels of this protein in USP8 mutated adenomas in the 350 
nucleus. However, possibly due to the small sample size (n=21), this discrepancy was 351 
statistically not significant. Introduction of the P720R USP8 mutation into At-T20 corticotroph 352 
cells increased the levels of phospho-CREB (figure 3(a) & (b)), suggesting that either pCREB 353 
or PKA is a direct client protein of USP8. The increased levels of phospho-CREB could lead 354 
in turn to enhanced ACTH secretion by activating the transcription of the POMC promoter 355 
(figure 4).  356 
The chaperone HSP90 was recently demonstrated to be overexpressed in corticotroph 357 
adenomas [16], resulting in increased inhibition of glucocorticoid receptor activity through 358 
HSP90-GR binding. Accordingly, GR is no longer able to efficiently inhibit POMC promoter 359 
activity and ACTH secretion [41]. In the cytoplasm of corticotroph adenomas, we did not 360 
observe differences in HSP90 protein abundance, however, we found significantly higher 361 
protein expression of HSP90 in the nuclei of USP8 mutated adenomas (figure 2(a) & (g)). Since 362 
mutated USP8 also shows a nuclear localization, one could speculate that HSP90 is a nuclear 363 
client protein of USP8 as HSP90 has been already demonstrated to bind GR and is localized 364 
in the nucleus [42]. Interestingly, the possible inhibition of GR action by increased HSP90 365 
protein levels in the context of USP8 mutations could be therapeutically relevant. Riebold and 366 
colleagues showed that inhibition of HSP90 with silibinin reduced ACTH secretion of At-T20 367 
cells both in vitro and in vivo [16], making this inhibitor particularly interesting for patients with 368 
CD tumors carrying USP8 mutations. 369 
One of the proteins where we observed differences between normal pituitary and corticotroph 370 
adenomas was the arginine vasopressin receptor 1b (AVPR1b) which in normal conditions is 371 
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activated by vasopressin, thereby potentiating the stimulating effects of CRH on ACTH 372 
secretion [43]. AVPR1b is the vasopressin receptor predominantly expressed on corticotroph 373 
cells of normal pituitaries and has been shown to be overexpressed in corticotroph adenomas 374 
[11-13]. In contrast, we observed a complete loss of the AVPR1b in corticotroph adenomas 375 
compared to normal pituitary tissue in our series. This might be due either to the small 376 
reference sample size (only 5 normal pituitaries) or (probably more likely) to the fact that our 377 
study investigated AVPR1b expression at protein level while all other studies analyzed mRNA 378 
expression only [11-13]. The decrease of AVPR1b might be due to increased vasopressin 379 
stimulation in corticotroph adenomas compared to normal pituitaries and somatotroph 380 
adenomas. We are well aware that this is not in line with the observed responsiveness of 381 
corticotroph adenomas /but not of other pituitary tumors) to desmopressin, a synthetic AVP 382 
analog that binds all three AVP receptors [13]. Nevertheless, it is well suitable to the 383 
observation that AVPR1b may be expressed in primary corticotropinoma cell cultures although 384 
the patients did not respond to desmopressin [44]. Of note, both USP8 WT and mutated 385 
samples had similarly low levels, indicating that this receptor might not be a direct substrate 386 
for USP8. Interestingly, the AVPR2 was much stronger and differentially expressed between 387 
different corticotroph tumors, with tumors being characterized by either high or low AVPR2 388 
expression, however, independent of the USP8 mutation status (figure 2(a) & (c)). Since 389 
desmopressin also binds this AVP receptor subtype, its high expression at least in some 390 
corticotroph tumors could possibly explain the responsiveness of corticotroph tumors to 391 
desmopressin. In addition, we observed reduced expression of HDAC2 in corticotroph tumors 392 
compared to normal pituitaries (figure 2(a) & (f)) as already described elsewhere [18]. This 393 
reduction was not as pronounced in USP8 mutated as in WT tumors, however, we can only 394 
speculate that this might be due to USP8 hyperactivity in mutated adenomas. 395 
However, all other proteins that have been demonstrated to be overexpressed in corticotroph 396 
adenomas compared to normal pituitaries (including GR, CRHR, cyclin E, and TR4) were 397 
unchanged between USP8 WT and mutated adenomas (figure 1 & 2). Although the activating 398 
role of CRHR and TR4 in ACTH secretion is well known, both are probably no client proteins 399 
of USP8; their overexpression in all corticotroph adenomas may have a different causality 400 
instead. For TR4, we also could not corroborate the results generated by Du et al. [17] who 401 
described an overexpression in corticotroph adenomas. 402 
Strengths and limitations 403 
To our knowledge, this is the largest study of corticotroph tumors with known USP8 mutation 404 
status in which 14 different corticotroph-relevant proteins were investigated. Due to the rarity 405 
of the tumor entity, samples had been collected multicentrically over the past decades. 406 
However, clinical follow-up of patients was not standardized and potentially interesting clinical 407 
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data (e.g. on remission rates or responsiveness to desmopressin) were unfortunately not 408 
available. 409 
 410 
Conclusion 411 
To summarize, our results demonstrate a possible role of USP8 mutations in the regulation of 412 
protein levels for several markers associated with corticotroph adenomas, most notably 413 
p27/kip1, CABLES1, HSP90, and activated CREB (figure 4), all of which have already been 414 
described as contributors to either ACTH hypersecretion or increased cell proliferation and CD 415 
[16]. These findings might have clinical relevance as an array of existing inhibitors could be 416 
used for tailoring the best therapy for CD patients with USP8 mutations, especially the HSP90 417 
inhibitor silibinin which is in clinical use and has been to shown to have an excellent safety 418 
record [45]. 419 
 420 
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Table 1: Clinical characteristics of patients with corticotroph adenomas. 532 
  USP8 WT 
USP8 
mutated 
p 
value 
Patients n (%) 58 (77) 17 (23)   
      
Age in years 54 (17-82) 38 (17-77) 0.02* 
Sex n (%)      
   Female 36 (62) 17 (100)  
   Male 22 (38) 0 (0)  
Maximum adenoma size in mm  10 (4-47) 10 (3-22) 0.14 
Body mass index in kg / m2  27 (20-46) 29 (19-46) 0.14 
      
Hormone levels prior surgery      
   ACTH  [pg/ml]bb median (n) 52 ± 106 (38) 68 ± 7 (13) 0.38 
   Cortisol [µg/dl] median (n) 16 ± 2.4 (43) 18 ± 2.6 (12) 0.11 
 533 
Results are given as median (range) 534 
 535 
 536 
Figure 1: Immunohistochemical investigation of pituitary adenomas (corticotroph, 537 
somatotroph and non-functioning) and normal pituitaries. (a) Exemplary staining of an 538 
USP8 WT and a mutated (mut) corticotroph adenoma for each protein investigated (scale bars: 539 
100µm). (b) H-score quantification of USP8 expression either in cytoplasm and membrane or 540 
in the nucleus. (c) H-score quantification of EGFR expression either in cytoplasm and 541 
membrane or in the nucleus. (d) H-score quantification of p27/kip1 expression either in 542 
cytoplasm and membrane or in the nucleus. (e) H-score quantification of cyclin E expression 543 
either in cytoplasm and membrane or in the nucleus. (f) H-score quantification of CREB 544 
expression either in cytoplasm and membrane or in the nucleus. (g) H-score quantification of 545 
phospho-CREB expression either in cytoplasm and membrane or in the nucleus. (h) H-score 546 
quantification of TR4 expression either in cytoplasm and membrane or in the nucleus. 547 
Abbreviations: GH = somatotroph adenomas, NF = non-functioning adenomas, nP = normal 548 
pituitary. 549 
 550 
 551 
 552 
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Figure 2: Immunohistochemical investigation of corticotroph pituitary adenomas and 553 
normal pituitaries. (a) Exemplary staining of an USP8 WT and a mutated (mut) corticotroph 554 
adenoma for each protein investigated (scale bars: 100µm). (b) H-score quantification of 555 
AVPR1b expression either in cytoplasm and membrane or in the nucleus. (c) H-score 556 
quantification of AVPR2 expression either in cytoplasm and membrane or in the nucleus. (d) 557 
H-score quantification of CRHR expression either in cytoplasm and membrane or in the 558 
nucleus. (e) H-score quantification of GR expression either in cytoplasm and membrane or in 559 
the nucleus. (f) H-score quantification of HDAC2 expression either in cytoplasm and 560 
membrane or in the nucleus. (g) H-score quantification of HSP90 expression either in 561 
cytoplasm and membrane or in the nucleus. (h) H-score quantification of CABLES1 expression 562 
either in cytoplasm and membrane or in the nucleus. Abbreviation: nP = normal pituitary. 563 
 564 
 565 
Figure 3: Western Blot (WB) results of USP8 WT and USP8 P720R mut introduction in 566 
At-T20 cells. (a) Exemplary WB of transfected At-T20 cells. (b) Densitometric analysis of WB 567 
USP8 bands normalized to loading control (α-tubulin) in comparison to mock transfected cells. 568 
(c) Densitometric analysis of WB p-CREB bands normalized to loading control in comparison 569 
to mock transfected cells. (d) Densitometric analysis of WB PKA Cα bands normalized to 570 
loading control in comparison to mock transfected cells. Analysis of three independent 571 
replicates. Overall P ns. 572 
 573 
 574 
Figure 4: Proposed action of USP8 in corticotroph pituitary adenomas. (a) USP8 WT 575 
conditions. To date it has not been ascertained if the three receptors AVPR1b /2 and CRHR 576 
are deubiquitinated by USP8 or not. The POMC promoter is normally activated by several 577 
transcription factors (including p-CREB) and is inhibited through binding of the glucocorticoid 578 
receptor (GR). HDAC2 deacetylates Histone H4 within the POMC promoter, leading to reduced 579 
transcription of the POMC gene. (b) Mutated USP8 is predominantly located in the nucleus, 580 
possibly allowing for targets that are also located within the nucleus. Here, HSP90 or pCREB 581 
expression is possibly higher due to USP8 hyperactivity. An increase in pCREB could lead to 582 
increased POMC expression and ACTH secretion. Increased HSP90 in the nucleus might be 583 
due to increased USP8 activity in the nucleus. This leads to increased HSP90-GR binding and 584 
reduced inhibition of the POMC promoter resulting in increased ACTH secretion. Strongly 585 
reduced levels of p27/kip1 are associated with USP8 mutations. This observation is also true 586 
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for CABLES1, however, neither p27/kip1 nor CABLES1 seem to be direct USP8 client proteins. 587 
Grey arrows without further specification symbolize USP8 deubiquitination action; grey 588 
inhibitory arrows demonstrate a blockage of normal protein activity; dashed arrow lines mean 589 
protein translocation; red arrows symbolize protein upregulation and red crosses symbolize a 590 
block in activity. 591 
